NCT02948777View on ClinicalTrials.gov

Effects of PCSK9 Inhibition by Evolocumab on Postprandial Lipid Metabolism in Type 2 Diabetes

PHASE4CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

June 30, 2018

Study Completion Date

June 30, 2018

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Evolocumab

Trial Locations (1)

Unknown

Helsinki University Hospital, Biomedicum 2U, Helsinki

All Listed Sponsors
collaborator

Göteborg University

OTHER

lead

Marja-Riitta Taskinen

OTHER

NCT02948777 - Effects of PCSK9 Inhibition by Evolocumab on Postprandial Lipid Metabolism in Type 2 Diabetes | Biotech Hunter | Biotech Hunter